[Somatostatin analogs in the clinical management of pituitary neoplasms].
The medical approach to patients with secreting or clinically non-functioning pituitary adenoma as made considerable progress thanks to the use of new somatostatin analogs. They were first used to treat acromegaly in the mid 1980s and numerous studies have shown a reduction in GH concentration in over 90% of acromegalic patients. Good results were obtained using slow-release analog treatment also in TSH-secreting adenomas, whereas the therapeutic efficacy of these peptides in clinically non-functioning adenomas is still controversial. Treatment with somatostatin analogs improves symptoms, normalises hormone secretion and in some cases may induce a reduction in the volume of pituitary adenomas. Scintigraphy with octreotide may help to select patients who respond to this form of treatment.
Colao
A
A
Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università degli Studi Federico II, Naples, Italy. calao@unina.it
Dorato
M
M
Pulcrano
M
M
Rossi
F W
FW
Auriemma
R S
RS
Lombardi
G
G
Lastoria
S
S
D000172:Acromegaly / Q000188:drug therapy; D000236:Adenoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging; D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002277:Carcinoma / Q000000981:diagnostic imaging; D006801:Humans; D007205:Indium Radioisotopes / Q000627:therapeutic use; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging; D008545:Melanoma / Q000000981:diagnostic imaging; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D010673:Pheochromocytoma / Q000000981:diagnostic imaging; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D011237:Predictive Value of Tests; D015175:Prolactinoma / Q000188:drug therapy; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D013004:Somatostatin / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use*; D013945:Thymoma / Q000000981:diagnostic imaging; D013953:Thymus Neoplasms / Q000000981:diagnostic imaging; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging; D013972:Thyrotropin / Q000378:metabolism; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D007205:Indium Radioisotopes; D010456:Peptides, Cyclic; D019275:Radiopharmaceuticals; C060347:lanreotide; C071632:SDZ 215-811; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D004369:Pentetic Acid; D013972:Thyrotropin; D015282:Octreotide